According to a research report "Plasma Fractionation Market is set to exhibit a notable CAGR of 6.7% Projected to reach USD 36.7 billion by 2027during the forecast period, up from its USD 26.5 billion value in 2022. The market's robust growth can be attributed to several key driving factors, including the rising application of immunoglobulins in treating various therapeutic areas such as hematology, neurology, and pulmonology. Additionally, the use of protease inhibitors to address lung diseases and hepatic diseases with a growing incidence rate further contributes to the market expansion.

Despite the promising growth prospects, the market faces certain challenges that could temper its progress. The increased cost of plasma products may create a barrier for some patients, and limited reimbursements could hinder accessibility for others. Moreover, the emergence and adoption of recombinant alternatives present a competitive challenge to plasma fractionation products.

the global plasma fractionation market is on a trajectory of growth, driven by the escalating application of immunoglobulins and protease inhibitors in various therapeutic treatments. However, challenges related to cost, reimbursement limitations, and the rise of recombinant alternatives demand careful consideration as stakeholders plan their strategies for the future.

Download Report Brochure @

The report also mentions that clinical research organizations, hospitals, and clinics are the key end-users of plasma fractionation products. These institutions require plasma-derived products for various research studies, clinical trials, and patient treatments.

Key Market Player:

The global plasma fractionation market is highly consolidated. The prominent players operating in this market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Istanbul), ADMA Biologics, Inc. (US), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India). Geographic expansions and collaborations are the key growth strategies undertaken by these companies to maintain their positions in the market.

Request Sample Report:

In 2021, the IVIG segment accounted for the largest share of the Immunoglobulins market

Based on immunoglobulins, the plasma fractionation market is segmented into into intravenous, subcutaneous, and other immunoglobulins. IVIG accounted for the largest share of the global Immunoglobulins market in 2021. The large share of this segment is primarily attributed to its use across various disease such as on label and off lable indiacations such as dermatomyositis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), immune cytopenias, hypogammaglobinemia, primary antibody deficiency, vacuities, multiple sclerosis, asthma, and systemic lupus erythematosus, among other ailments. Also the shorter rapid response period of IVIG than steroids or oral immunosuppressants, the increasing investments in healthcare and the rising number of patients suffering from autoimmune diseases and other pathological conditions is key for the growth of this market segment

The pulmonology segment is expected to grow at the highest CAGR during the forecast period

Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. In 2021, the pulmonology segment is expected to register the highest CAGR during the forecast period. Growth in this market segment is driven largely significantly increased use of protease inhibitors, such as alpha-1-antitrypsin in recent years. Also, with the rising geriatric population, the prevalence of AATD and COPD is expected to increase across the globe. With the rising incidence of target diseases, the demand for plasma-derived alpha-1-antitrypsin is expected to increase in the coming years making the pulmonogly segment the fastest growing during the forecast period.

North America was the largest regional market for plasma fractionation market in 2021

The global plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the innovations in manufacturing processes such as presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA, high number of registered hemophilic patients and largest number of plasma collection center. However, the market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growth in increasing number of hemophilic patients, as well as factors such as the increasing number of organ transplantations, modified regulations and monitoring of the implementation of procedures, policies, and guidelines to promote innovation and commercialization, increasing awareness about technologically advanced products in the region, and the improving standard of living across several APAC countries.

Request 10% Customization:

Recent Development:

  • Baxter International Inc. acquired ChemoSera S.A. in 2022. The acquisition will expand Baxter’s portfolio of plasma fractionation products and enable the company to expand its presence in the European markets.
  • Biovian Oy acquired ViroClinics Biosciences B.V. in 2022. The acquisition will expand Biovian’s plasma fractionation capabilities, increase its global presence, and enable the company to enhance its offerings in the field of plasma-derived biopharmaceuticals.
  • Takeda Pharmaceutical Company Limited acquired Shire Plc in 2022. This acquisition will broaden Takeda’s product portfolio, enabling the company to expand its presence in the plasma fractionation market.
  • Grifols S.A. acquired Hologic Inc. in 2022. The acquisition of Hologic’s business will enable Grifols to expand its offering of plasma fractionation products and services, as well as its global presence.
  • CSL Limited acquired Terumo BCT in 2023. This acquisition will enable CSL to expand its product portfolio and strengthen its position in the global plasma fractionation market.

Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website:

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.